Loading...
We have set up our new Discord server! Share your feedback and find like-minded people! Join our Discord
- Ticker
- AGY.LSE
- Price
- 6.90
- Stock movement up
- +- (%)
- Company name
- Allergy Therapeutics
- Exchange
- (LSE ,
- Currency
- GBX )
- Sector
- Healthcare >Drug Manufacturers - Specialty & Generic
- Market cap
- 32.89B
- Ent value
- -
- Price/Sales
- -
- Price/Book
- -
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- -
- Forward P/E
- -
- PEG
- -
- EPS growth
- -
- 1 year return
- 31.43%
- 3 year return
- -42.07%
- 5 year return
- -9.71%
- 10 year return
- -11.44%
Last updated: 2025-08-27
DIVIDENDS
AGY.LSE does not pay dividends or no data was received
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | - |
| EV to EBITDA | - |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | - |
| Price to Book | - |
| EV to Sales | - |
FINANCIALS
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 7.00 |
| Daily high | 7.35 |
| Daily low | 6.68 |
| Daily Volume | 244K |
| All-time high | 141.00 |
| 1y analyst estimate | 13.00 |
| Beta | 1.02 |
| EPS (TTM) | - |
| Dividend per share | - |
| Ex-div date | - |
| Next earnings date | 24 Sep 2025 |
Downside potential
Loading...
Downside potential data
| AGY.LSE | S&P500 | |
| Current price drop from All-time high | -95.11% | -3.04% |
| Highest price drop | -99.38% | -56.47% |
| Date of highest drop | 29 Jun 2023 | 9 Mar 2009 |
| Avg drop from high | -77.77% | -11.04% |
| Avg time to new high | 196 days | 12 days |
| Max time to new high | 4359 days | 1805 days |
COMPANY DETAILS
Marketcap
32.89B
Marketcap category
Large-cap
Description
Allergy Therapeutics plc, a commercial biotechnology company, focuses on the diagnosis and treatment of allergic disorders. The company sells injectable and sublingual allergen-specific immunotherapies; and offers treatment of pollen-related allergies particularly to grasses, weeds, and trees, as well as diagnostics products. Its products include Pollinex Quattro, Oralvac, Venomil, Venom ATL Polistes Dominula, Synbiotics, and Acarovac Plus. It also develops Grass MATA MPL, a subcutaneous allergen-specific immunotherapy candidate that aims to address the cause of symptoms of allergic rhinoconjunctivitis due to grass pollen; and VLP Peanut, a short-course peanut allergy vaccine. The company operates in Germany, Austria, Netherlands, Switzerland, Italy, Spain, and internationally, as well as the United Kingdom. Allergy Therapeutics plc was founded in 1998 and is headquartered in Worthing, the United Kingdom.
Employees
0
Investor relations
-
SEC filings
CEO
Country
UK
City
Stock type
-
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
All newsPress releases
No items found